Studio Zimmer Continuum Metal on Polyethylene (MoP) Postmarketing Clinical Followup (PMCF).
Studio prospettico di follow-up clinico post-vendita del sistema acetabolare in metallo continuo su polietilene
This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
California
-
Fremont, California, Stati Uniti, 94538
- Sah Orthopaedic Associates
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80204
- Denver Health Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients from surgeons medical practice who are candidates for primary hip arthroplasty.
The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.
Descrizione
Inclusion Criteria
-
Patient is 18 to 75 years of age, inclusive.
-
Patient is skeletally mature.
-
Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:
- Avascular necrosis (AVN)
- Osteoarthritis
- Inflammatory arthritis (i.e., Rheumatoid arthritis)
- Post-traumatic arthritis
-
Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
-
Patient has moderate, marked or disabling pain.
-
Patient is willing and able to provide written informed consent.
-
Patient is willing and able to cooperate in the required post-operative therapy.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
-
Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.
Exclusion Criteria:
-
The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails
- A known alcohol or drug abuser
- Anticipated to be non-compliant
-
The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
-
The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
-
The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
-
The patient is known to be pregnant.
-
The patient is unwilling or unable to give consent or to comply with the follow-up program.
-
The patient has received an investigational drug or device within the previous 6 months.
-
The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
-
The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
-
The patient has osteoradionecrosis in the affected hip joint.
-
The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
-
The patient has known local bone tumors and/or cysts in the operative hip.
-
The patient has a Body Mass Index (BMI) > 40.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Continuum Acetabular System
Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System |
Used in primary hip arthroplasty
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Survivorship
Lasso di tempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Safety / Adverse Events
Lasso di tempo: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects. |
Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pain and Function / HHS
Lasso di tempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Harris Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Pain and Function / OHS
Lasso di tempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Oxford Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / SF-12
Lasso di tempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Health status will be measured using the SF-12 self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / Radiographic Parameters
Lasso di tempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Metal Ion / Cobalt
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Chromium
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Titanium
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / BUN
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / Creatinine
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / GFR
Lasso di tempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Hillary Overholser, Zimmer Biomet
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie ossee
- Malattie muscoloscheletriche
- Processi patologici
- Malattie articolari
- Malattie reumatiche
- Malattie del tessuto connettivo
- Malattie autoimmuni
- Malattie del sistema immunitario
- Necrosi
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Artrite
- Osteoartrite
- Artrite, reumatoide
- Osteonecrosi
- Procedure chirurgiche, operative
- Artroplastica, sostituzione
- Artroplastica
- Procedure ortopediche
- Procedure di chirurgia plastica
- Impianto di protesi
- Artroplastica, sostituzione, anca
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CMU2010-02H
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .